vs
Ginkgo Bioworks Holdings, Inc.（DNA）与HERITAGE COMMERCE CORP（HTBK）财务数据对比。点击上方公司名可切换其他公司
HERITAGE COMMERCE CORP的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$53.6M vs $33.4M），HERITAGE COMMERCE CORP同比增速更快（15.6% vs -23.8%），HERITAGE COMMERCE CORP自由现金流更多（$61.3M vs $-47.7M），过去两年HERITAGE COMMERCE CORP的营收复合增速更高（12.8% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
本文介绍的企业主体信息与内容描述不符，描述内容实际为美国商会，该商会成立于1912年4月23日，是美国规模最大的游说类商业协会 advocacy 团体，成立之初得益于时任总统威廉·霍华德·塔夫脱与劳工商务部长查尔斯·内格尔推动，旨在代表工商界发声。
DNA vs HTBK — 直观对比
营收规模更大
HTBK
是对方的1.6倍
$33.4M
营收增速更快
HTBK
高出39.5%
-23.8%
自由现金流更多
HTBK
多$109.0M
$-47.7M
两年增速更快
HTBK
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $53.6M |
| 净利润 | — | $15.1M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 41.0% |
| 净利率 | — | 28.2% |
| 营收同比 | -23.8% | 15.6% |
| 净利润同比 | — | 42.3% |
| 每股收益（稀释后） | $-1.41 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAHTBK
| Q4 25 | $33.4M | $53.6M | ||
| Q3 25 | $38.8M | $50.0M | ||
| Q2 25 | $49.6M | $47.8M | ||
| Q1 25 | $48.3M | $46.1M | ||
| Q4 24 | $43.8M | $46.4M | ||
| Q3 24 | $89.0M | $42.2M | ||
| Q2 24 | $56.2M | $41.7M | ||
| Q1 24 | $37.9M | $42.1M |
净利润DNAHTBK
| Q4 25 | — | $15.1M | ||
| Q3 25 | $-80.8M | $14.7M | ||
| Q2 25 | $-60.3M | $6.4M | ||
| Q1 25 | $-91.0M | $11.6M | ||
| Q4 24 | — | $10.6M | ||
| Q3 24 | $-56.4M | $10.5M | ||
| Q2 24 | $-217.2M | $9.2M | ||
| Q1 24 | $-165.9M | $10.2M |
营业利润率DNAHTBK
| Q4 25 | -211.9% | 41.0% | ||
| Q3 25 | -231.8% | 41.1% | ||
| Q2 25 | -132.1% | 18.7% | ||
| Q1 25 | -184.1% | 35.4% | ||
| Q4 24 | -236.3% | 31.8% | ||
| Q3 24 | -62.0% | 34.3% | ||
| Q2 24 | -396.7% | 31.3% | ||
| Q1 24 | -469.1% | 34.2% |
净利率DNAHTBK
| Q4 25 | — | 28.2% | ||
| Q3 25 | -207.9% | 29.4% | ||
| Q2 25 | -121.6% | 13.4% | ||
| Q1 25 | -188.2% | 25.2% | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | -63.3% | 24.9% | ||
| Q2 24 | -386.4% | 22.1% | ||
| Q1 24 | -437.3% | 24.1% |
每股收益（稀释后）DNAHTBK
| Q4 25 | $-1.41 | $0.25 | ||
| Q3 25 | $-1.45 | $0.24 | ||
| Q2 25 | $-1.10 | $0.10 | ||
| Q1 25 | $-1.68 | $0.19 | ||
| Q4 24 | $-1.91 | $0.17 | ||
| Q3 24 | $-1.08 | $0.17 | ||
| Q2 24 | $-4.23 | $0.15 | ||
| Q1 24 | $-3.32 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $708.6M |
| 总资产 | $1.1B | $5.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAHTBK
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
股东权益DNAHTBK
| Q4 25 | $508.6M | $708.6M | ||
| Q3 25 | $559.8M | $700.0M | ||
| Q2 25 | $613.0M | $694.7M | ||
| Q1 25 | $647.4M | $696.2M | ||
| Q4 24 | $716.1M | $689.7M | ||
| Q3 24 | $797.9M | $685.4M | ||
| Q2 24 | $833.1M | $679.2M | ||
| Q1 24 | $987.3M | $676.3M |
总资产DNAHTBK
| Q4 25 | $1.1B | $5.8B | ||
| Q3 25 | $1.2B | $5.6B | ||
| Q2 25 | $1.2B | $5.5B | ||
| Q1 25 | $1.3B | $5.5B | ||
| Q4 24 | $1.4B | $5.6B | ||
| Q3 24 | $1.5B | $5.6B | ||
| Q2 24 | $1.6B | $5.3B | ||
| Q1 24 | $1.6B | $5.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $61.7M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $61.3M |
| 自由现金流率自由现金流/营收 | -142.8% | 114.3% |
| 资本支出强度资本支出/营收 | 0.0% | 0.7% |
| 现金转化率经营现金流/净利润 | — | 4.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DNAHTBK
| Q4 25 | $-47.7M | $61.7M | ||
| Q3 25 | $-31.6M | $18.9M | ||
| Q2 25 | $-40.3M | $8.0M | ||
| Q1 25 | $-51.5M | $14.8M | ||
| Q4 24 | $-42.4M | $39.0M | ||
| Q3 24 | $-103.5M | $5.3M | ||
| Q2 24 | $-84.4M | $10.5M | ||
| Q1 24 | $-89.3M | $7.3M |
自由现金流DNAHTBK
| Q4 25 | $-47.7M | $61.3M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-59.1M | — | ||
| Q4 24 | $-56.1M | $37.3M | ||
| Q3 24 | $-118.6M | $4.9M | ||
| Q2 24 | $-111.4M | $9.9M | ||
| Q1 24 | $-96.0M | $6.9M |
自由现金流率DNAHTBK
| Q4 25 | -142.8% | 114.3% | ||
| Q3 25 | — | 37.7% | ||
| Q2 25 | -81.2% | — | ||
| Q1 25 | -122.4% | — | ||
| Q4 24 | -128.0% | 80.5% | ||
| Q3 24 | -133.2% | 11.6% | ||
| Q2 24 | -198.2% | 23.6% | ||
| Q1 24 | -252.9% | 16.4% |
资本支出强度DNAHTBK
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 31.3% | 3.5% | ||
| Q3 24 | 16.9% | 1.0% | ||
| Q2 24 | 48.1% | 1.6% | ||
| Q1 24 | 17.7% | 1.0% |
现金转化率DNAHTBK
| Q4 25 | — | 4.08× | ||
| Q3 25 | — | 1.28× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.67× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | — | 0.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
HTBK
暂无分部数据
